Cargando…

The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer

ErbB2 overexpression identifies a subclass of breast cancer as ErbB2-positive that is frequently associated with poor prognosis. Current ErbB2-targeted therapies have profoundly improved patient outcomes, but mutations occurring in ErbB2 have been shown to confer drug resistance. Induction of ErbB2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Jinrui, Liu, Shuyan, Li, Qiong, Shi, Yulin, Wu, Yueguang, Liu, Fang, Wang, Shanshan, Zaky, Mohamed Y., Yousuf, Waleed, Sun, Qianhui, Guo, Dong, Wang, Taishu, Zhang, Yingqiu, Wang, Yang, Li, Man, Liu, Han
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429833/ https://www.ncbi.nlm.nih.gov/pubmed/32327714 http://dx.doi.org/10.1038/s41418-020-0538-8

Ejemplares similares

Cholesterol content in cell membrane maintains surface levels of ErbB2 and confers a therapeutic vulnerability in ErbB2-positive breast cancer
por: Zhang, Jinrui, et al.
Publicado: (2019)

Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1
por: Li, Guangyuan, et al.
Publicado: (2014)

A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors
por: Meng, Y, et al.
Publicado: (2016)

Mutational Screening in Tyrosine-Kinase Domain of erbB1 And erbB2 Genes
por: ALONSO, Juan Manuel Fernández
Publicado: (2005)

Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer
por: Wolfson, Eya, et al.
Publicado: (2018)

Nucleolin-binding by ErbB2 enhances tumorigenicity of ErbB2-positive breast cancer
por: Wolfson, Eya, et al.
Publicado: (2016)

Proliferation of Colorectal Cancer Is Promoted by Two Signaling Transduction Expression Patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK
por: Yao, Yong-Liang, et al.
Publicado: (2013)

Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer
por: Roepstorff, Kirstine, et al.
Publicado: (2008)

DEPTOR stabilizes ErbB2 to promote the proliferation and survival of ErbB2-positive breast cancer cells
por: Bi, Yanli, et al.
Publicado: (2021)

Expression of oncogenes in thyroid tumours: coexpression of c-erbB2/neu and c-erbB.
por: Aasland, R., et al.
Publicado: (1988)

erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification.
por: Colomer, R., et al.
Publicado: (1994)

Development of ErbB2-Targeting Liposomes for Enhancing Drug Delivery to ErbB2-Positive Breast Cancer
por: Ueno, Sho, et al.
Publicado: (2020)

FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion
por: Benlimame, Naciba, et al.
Publicado: (2005)

Endocrine resistance in breast cancer: new roles for ErbB3 and ErbB4
por: Sutherland, Robert L
Publicado: (2011)

ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC
por: Alvarado, Diego, et al.
Publicado: (2017)

Betacellulin-Induced Beta Cell Proliferation and Regeneration Is Mediated by Activation of ErbB-1 and ErbB-2 Receptors
por: Oh, Yoon Sin, et al.
Publicado: (2011)

Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting
por: Singer, Josef, et al.
Publicado: (2012)

Quantitative Analysis of ErbB1 and ErbB2 Genes Amplification by a High Performance Liquid Chromatography
por: Rasti, Mozhgan, et al.
Publicado: (2014)

Effects of ErbB2 Overexpression on the Proteome and ErbB Ligand-specific Phosphosignaling in Mammary Luminal Epithelial Cells
por: Worthington, Jenny, et al.
Publicado: (2017)

Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence
por: Pandya, K, et al.
Publicado: (2011)

DMBA promotes ErbB2-mediated carcinogenesis via ErbB2 and estrogen receptor pathway activation and genomic instability
por: Ma, Zhikun, et al.
Publicado: (2018)

Spinal nerve injury causes upregulation of ErbB2 and ErbB3 receptors in rat dorsal root ganglia
por: Mizobuchi, Satoshi, et al.
Publicado: (2013)

ErbB3-binding protein EBP1 decreases ErbB2 levels via a transcriptional mechanism
por: GHOSH, ARUNDHATI, et al.
Publicado: (2012)

Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer
por: Ghasemi, R, et al.
Publicado: (2014)

Shc3 facilitates breast cancer drug resistance by interacting with ErbB2 to initiate ErbB2/COX2/MDR1 axis
por: Liu, Yun, et al.
Publicado: (2023)

Valproic acid exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs
por: Lin, Tingting, et al.
Publicado: (2019)

ErbB2 Dephosphorylation and Anti-Proliferative Effects of Neuregulin-1 in ErbB2-Overexpressing Cells; Re-evaluation of Their Low-Affinity Interaction
por: Wang, Ran, et al.
Publicado: (2013)

The Role of ErbB Receptors in Infection
por: Ho, Jemima, et al.
Publicado: (2017)

Photo-Activated Psoralen Binds the ErbB2 Catalytic Kinase Domain, Blocking ErbB2 Signaling and Triggering Tumor Cell Apoptosis
por: Xia, Wenle, et al.
Publicado: (2014)

ErbB1 and ErbB3 co-over expression as a prognostic factor in gastric cancer
por: Moghbeli, Meysam, et al.
Publicado: (2019)

Identification of prolidase as a high affinity ligand of the ErbB2 receptor and its regulation of ErbB2 signaling and cell growth
por: Yang, L, et al.
Publicado: (2014)

Activated Akt1 accelerates MMTV-c-ErbB2 mammary tumourigenesis in mice without activation of ErbB3
por: Young, Christian D, et al.
Publicado: (2008)

Neuregulin-1-mediated ErbB2–ErbB3 signalling protects human trophoblasts against apoptosis to preserve differentiation
por: Fock, Valerie, et al.
Publicado: (2015)

BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors
por: Miele, Evelina, et al.
Publicado: (2020)

The Mysterious Ways of ErbB2/HER2 Trafficking
por: Bertelsen, Vibeke, et al.
Publicado: (2014)

Molecular architecture of the ErbB2 extracellular domain homodimer
por: Hu, Shi, et al.
Publicado: (2015)

Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer
por: Wang, Shuiliang, et al.
Publicado: (2013)

C-erbB2 mRNA expression in human breast tumours: comparison with c-erbB2 DNA amplification and correlation with prognosis.
por: Parkes, H. C., et al.
Publicado: (1990)

Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant mammary tissues of MMTV-erbB-2 transgenic mice
por: Parris, Amanda B., et al.
Publicado: (2017)

Coordinate transcriptional regulation of ErbB2/3 by C-terminal binding protein 2 signals sensitivity to ErbB2 inhibition in pancreatic adenocarcinoma
por: Chougoni, Kranthi Kumar, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_it4mahldsc3f84206v3vvjgujc